Latest Articles

Publication Date
All News Scientific
IGF2BP2-modified circular RNA circCHD7 promotes endometrial cancer progression via stabilizing PDGFRB and activating JAK/STAT signaling pathway - Nature.com

IGF2BP2-modified circular RNA circCHD7 promotes endometrial cancer progression via stabilizing PDGFRB and activating JAK/STAT signaling pathway Nature.com

Published: May 22, 2024, 7 a.m.
Read Full Article
Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer - OncLive

Dr Bou Farhat on a Retrospective Study of NGS vs IHC Sensitivity for dMMR CRC and Endometrial Cancer OncLive

Published: May 21, 2024, 7 a.m.
Read Full Article
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous Ovarian Cancer - GlobeNewswire

eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer and in Low Grade Serous …

Published: May 20, 2024, 7 a.m.
Read Full Article
Plaintiffs Seek To Dismiss Hair Relaxer Lawsuits Involving Women Not Diagnosed with Uterine, Endometrial or Ovarian Cancer - AboutLawsuits.com

Plaintiffs Seek To Dismiss Hair Relaxer Lawsuits Involving Women Not Diagnosed with Uterine, Endometrial or Ovarian Cancer AboutLawsuits.com

Published: May 15, 2024, 8:32 p.m.
Read Full Article
Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer - OncLive

Dr Corr on the Rationale for Investigating Rucaparib Maintenance in Endometrial Cancer OncLive

Published: May 10, 2024, 7 a.m.
Read Full Article
Merck's endometrial cancer therapy fails trial - Reuters

Merck's endometrial cancer therapy fails trial Reuters

Published: May 9, 2024, 7 a.m.
Read Full Article
Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer - AJMC.com Managed Markets Network

Postsurgical Pembrolizumab and Chemo, With or Without Radiotherapy, Falls Short in Phase 3 Trial for Newly Diagnosed, High-Risk Endometrial Cancer AJMC.com Managed Markets Network

Published: May 9, 2024, 7 a.m.
Read Full Article
Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer - FiercePharma

Merck's Keytruda plus chemo comes up short as post-surgery therapy in newly diagnosed endometrial cancer FiercePharma

Published: May 9, 2024, 7 a.m.
Read Full Article
Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint - Healio

Phase 3 trial evaluating Keytruda in endometrial cancer misses primary survival endpoint Healio

Published: May 9, 2024, 7 a.m.
Read Full Article
Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop - BioSpace

Keytruda Strikes Out Again in Endometrial Cancer with Phase III Flop BioSpace

Published: May 9, 2024, 7 a.m.
Read Full Article
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!